Royal Bank Of Canada Lowers Diaceutics (LON:DXRX) Price Target to GBX 185

Diaceutics (LON:DXRX) had its price target reduced by equities researchers at Royal Bank Of Canada from GBX 195 ($2.63) to GBX 185 ($2.50) in a research note issued on Thursday, Marketbeat Ratings reports. The brokerage currently has an “outperform” rating on the stock. Royal Bank Of Canada’s price objective points to a potential upside of 55.46% from the stock’s previous close.

Diaceutics Stock Up 2.1%

Shares of DXRX opened at GBX 119 ($1.61) on Thursday. Diaceutics has a 52 week low of GBX 106 ($1.43) and a 52 week high of GBX 151 ($2.04). The company has a debt-to-equity ratio of 0.39, a quick ratio of 9.92 and a current ratio of 4.85. The firm’s 50-day simple moving average is GBX 124.79 and its 200 day simple moving average is GBX 128.57. The firm has a market cap of £100.43 million, a P/E ratio of -35.29 and a beta of 0.58.

Diaceutics (LON:DXRX) last announced its earnings results on Tuesday, May 13th. The company reported GBX (2.02) (($0.03)) earnings per share (EPS) for the quarter. Diaceutics had a negative net margin of 10.90% and a negative return on equity of 7.15%. On average, analysts forecast that Diaceutics will post 1.0107919 earnings per share for the current year.

Insider Activity at Diaceutics

In other news, insider Peter Keeling sold 500,000 shares of the business’s stock in a transaction on Tuesday, May 13th. The shares were sold at an average price of GBX 126 ($1.70), for a total transaction of £630,000 ($849,858.36). 34.30% of the stock is currently owned by insiders.

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world’s leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX – The Diagnostics Network®.